Medicines Optimisation Centricity: Understanding the deprescribing landscape

Overview In March 2026, the fourth instalment of Medicines Optimisation Centricity, the ongoing collaboration between Aspire Pharma and HSJ Information, commenced. The programme brings together key NHS and pharmacy stakeholders to explore…

Menopause and Skin Health: Insights from Aspire Pharma and National Eczema Society

Research conducted by Aspire Pharma and National Eczema Society in October 2024, revealed the often-hidden impact of menopause on skin health, with many women encountering unexpected issues like dry skin and eczema as they undergo hormonal changes.   The…

Medicines Optimisation Centricity – Reimagining Value in the Patient Pathway

Executive Summary: Medicines Optimisation Centricity – Reimagining Value in the Patient Pathway Overview This white paper, developed by HSJ Advisory in partnership with Aspire Pharma, presents a compelling case for transforming medicines…

Reimagining Medicines Optimisation: A Call to Action for Addressing Health Inequalities

Petersfield, Hampshire, 30 October 2024 – Aspire Pharma Ltd in 2023 spearheaded an important initiative called Medicines Optimisation Centricity and initiated a White Paper published in May 2023 via Health Service Journal (HSJ), which urged…

Medicines Optimisation Centricity – addressing Access & Choice to Medicine Inequalities and Inequities

Petersfield, Hampshire, 01 October 2024, Aspire Pharma Ltd has initiated and funded a new report on improving access and choice to medicines by bringing the patient into the centre of the decision-making process; which follows the publication…

Medicines Optimisation Centricity – Getting It Right

Petersfield, Hampshire, 01 November 2023, Aspire Pharma Ltd initiated and funded the set-up of a series of round table events to discuss Medicines Optimisation Centricity. These events, facilitated by Wilmington Healthcare, as a data intelligence…